Arquivos Mensais: October 2009

Industry Years Behind on Testing Approved Drugs

WASHINGTON — Federal drug officials have long been criticized for failing to force drug makers to complete studies proving that their drugs work as hoped, and Congressional investigators on Monday released yet another report pointing out that some of these

Publicado em Around the Globe

Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.

Dapsone is a chemotherapeutic agent primarily used in treating leprosy, Pneumocystis jiroveci (previously carinii) pneumonia, and malaria. It is also used as an adjuvant in the treatment of pemphigus and pemphigoid.

Publicado em Around the Globe

Patients protest losing drug coverage

ALBUQUERQUE (KRQE) – A group of New Mexicans is protesting changes by Presbyterian Health Plan that now deny them a drug they say was effective in fighting their rare disease.

Publicado em Around the Globe

Stimulus funds boost electronic health records

The national health care debate continues on Capitol Hill, but that won’t stop Springfield medical leaders from injecting innovation into the local health care scene.

Publicado em Around the Globe

Virus Is Found in Many With Chronic Fatigue Syndrome

Many people with chronic fatigue syndrome are infected with a little known virus that may cause or at least contribute to their illness, researchers are reporting.

Publicado em Around the Globe

A New Web Tool to Take Control of Your Health

The national health care debate right now is all about giving more people affordable access to doctors and hospitals. Yet the vast majority of health care decisions — 80 percent or more, experts say — are really made by individuals,

Publicado em Around the Globe

Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study

Bullous pemphigoid (BP), pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are autoimmune bullous diseases characterized by the presence of tissue-bound and circulating autoantibodies directed against disease-specific target antigens of the skin. Although rare, these diseases run a chronic course and

Publicado em Around the Globe

JOIN TODAY!

The P/P Registry has been approved by the Western Institutional Review Board (WIRB) and is actively enrolling participants.

ENGLISH VERSION

SPANISH VERSION